AKT1 and lung disorder: If rosiglitazone indeed facilitates re-phosphorylation of Akt, then it would result in a pro-fibrotic response that undercuts its anti-fibrotic effects, suggesting that rosiglitazone is not an optimal choice for treating fibrotic lung diseases.